Business Context and Reporting Period
Company: Pyxis Oncology, Inc. (PYXS)
Filing Type: Form 8-K (Current Report)
Date: December 18, 2025
Primary Event: Announcement of positive preliminary Phase 1 clinical data for micvotabart pelidotin (MICVO) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and a corporate update regarding asset monetization.
Key Financial Metrics and Liquidity
Revenue and Profit: The filing does not provide specific revenue, profit, or margin figures for a reporting period.
Cash Flow and Liquidity:
- Asset Sale: Completed the sale of royalty rights for Enzeshu (Suvemcitug) for a one-time cash payment of $11 million.
- Runway: Current cash position is expected to fund operations through data milestones and into the fourth quarter of 2026.
Material Changes and Clinical Data
The filing details significant clinical progress for MICVO, a first-in-concept antibody-drug conjugate (ADC) targeting EDB+FN. Data cutoff was November 3, 2025.
Monotherapy (Phase 1, 5.4 mg/kg)
- Patient Population: 18 patients treated; 13 evaluable. All had prior systemic therapy (median 3 lines), including 100% prior platinum and 100% prior checkpoint inhibitor therapy.
- Efficacy: Confirmed Overall Response Rate (ORR) of 46% (6/13), including 1 complete response. Disease Control Rate (DCR) was 92% (12/13).
- Safety: Generally well tolerated. No Grade 4 or 5 treatment-related adverse events (TRAEs) of interest. 56% of patients experienced Grade 3+ TRAEs. 28% discontinued due to TRAEs, all of whom were "high bodyweight" patients.
- Adjustment: Future studies will implement Adjusted Ideal Bodyweight (AIBW) dosing to improve tolerability.
Combination Therapy (Phase 1/2 with KEYTRUDA)
- Patient Population: 7 patients treated (4 at 3.6 mg/kg, 3 at 4.4 mg/kg) plus pembrolizumab. All were HPV-positive.
- Efficacy: Confirmed ORR of 71% (5/7). DCR of 100% (7/7). Responses observed in patients with prior checkpoint inhibitor progression.
- Safety: No Grade 3 or 4 ADC payload TRAEs of interest. No TRAEs led to discontinuation. No overlapping toxicities with KEYTRUDA observed.
Outlook, Risks, and Management Commentary
Outlook: Management anticipates enrolling HPV-negative and HPV-not applicable patients in the combination study as global sites activate. The $11 million non-dilutive funding from the Enzeshu royalty sale will support MICVO development.
Risks and Contingencies:
- Forward-Looking Statements: The filing contains forward-looking statements regarding clinical trial timing, results, and cash runway, which are subject to risks and uncertainties.
- Operational Risk: Tolerability issues observed in high bodyweight patients in monotherapy require dosing adjustments (AIBW) in future studies.
- Regulatory Risk: The press release and presentation attached as exhibits are not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific terms and timing of the $11 million royalty sale for Enzeshu.
- Confirm the implementation timeline for Adjusted Ideal Bodyweight (AIBW) dosing in upcoming MICVO trials.
- Monitor the enrollment progress of HPV-negative patients in the MICVO + KEYTRUDA combination study.
- Review the full clinical data presentation (Exhibit 99.2) for detailed safety profiles and individual patient response data.
- Assess the company's cash burn rate relative to the stated runway into Q4 2026.